Important COVID Vaccination Program Guidance (Oct. 25, 2021)
Important COVID Vaccination Program Guidance (Oct. 25, 2021) The attached information was sent to all providers enrolled in the NYS COVID-19 vaccination program. It is updated to reflect the FDA authorization and CDC approval of Moderna and J&J booster doses for eligible individuals and the administration of heterologous booster doses.
Recommendations for a single dose of the Pfizer-BioNTech COVID-19 Vaccine
Dear COVID-19 Vaccination Provider: On September 24, 2021, under the U.S. Food and Drug Administration’s (FDA) updated emergency use authorization (EUA), the CDC issued recommendations for a single dose of the Pfizer-BioNTech COVID-19 Vaccine at least six months after completion of the primary series for the following individuals: individuals 65 years
Pfizer-BioNTech COVID-19 Vaccine Licensure and Expiration Extension
Pfizer-BioNTech COVID-19 Vaccine Licensure and Expiration Extension Dear COVID-19 Vaccination Provider, The FDA granted full licensure for Pfizer's COVID-19 vaccine on August 23, 2021. The full licensure applies to the use of this vaccine in the 16+ population. The vaccine also continues to be available under emergency use authorization (EUA) for adolescents 12 through
Janssen/Johnson & Johnson COVID-19 Vaccine Expiration Extension
Janssen/Johnson & Johnson COVID-19 Vaccine Expiration Extension On July 29, 2021, the U.S. Food & Drug Administration (FDA) authorized an extension of the shelf life for the Janssen/Johnson & Johnson (J&J) single-shot COVID-19 vaccine by 45 days, from 4.5 months to 6 months. The decision is based on data from ongoing
Important Information regarding Janssen/Johnson & Johnson (J&J) COVID-19 Vaccine
Important Information regarding Janssen/Johnson & Johnson (J&J) COVID-19 Vaccine On July 13, 2021, the U.S. Food and Drug Administration (FDA) announced revisions to the Emergency Use Authorization (EUA) fact sheets for the Janssen/Johnson & Johnson (J&J) COVID-19 vaccine to include information regarding an observed increased risk of Guillain-Barre Syndrome (GBS)
Provider Support for Excelsior Pass COVID-19 Vaccination Data
Dear COVID-19 Vaccination Program Provider: This message is being sent to all COVID-19 Vaccination Program enrolled providers in an effort to increase vaccinated individuals’ ability to obtain an Excelsior Pass. If you have not yet administered COVID-19 vaccine, you may disregard this message. Excelsior Pass mobile application is New York
JJ COVID Vaccine Extension
Important Information regarding Janssen/Johnson & Johnson (J&J) COVID-19 Vaccine On July 13, 2021, the U.S. Food and Drug Administration (FDA) announced revisions to the Emergency Use Authorization (EUA) fact sheets for the Janssen/Johnson & Johnson (J&J) COVID-19 vaccine to include information regarding an observed increased risk of Guillain-Barre Syndrome (GBS)
“Universal Dose” Administration Process
Dear Enrolled Provider: Effective today, May 11th, New York State is moving to a “Universal Dose” administration process for all multi-dose COVID-19 vaccine types. All doses are now considered universal doses, which means that doses can be used for a first dose or a second dose, irrespective as to whether they were originally shipped to providers as a first
NYS DOH Commissioner has released a statement regarding the Johnson & Johnson vaccine
NYS Department of Health Commissioner Dr. Howard Zucker released the following statement regarding the Johnson & Johnson vaccine: "Today the CDC and FDA issued a statement recommending a pause in the use of the Johnson & Johnson vaccine out of an abundance of caution. New York State will follow the CDC and FDA
NYS Physicians Practices Begin to Receive COVID-19 Vaccine
NYS Physicians Practices Begin to Receive COVID-19 Vaccine Physicians are Encouraged to Take NYS DOH Survey Today, the Medical Society of the State of New York was notified by the New York State Department of Health that 27,100 Moderna doses were allocated to 190 enrolled COVID-19 providers. All physicians
